← All Redhill Biopharma LTD filings

Redhill Biopharma LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
RDHL
Redhill Biopharma LTD
20-F: RedHill Biopharma Faces Going Concern Doubt Amidst Financial Challenges
RedHill Biopharma Ltd.'s Form 20-F filing for the fiscal year ended December 31, 2025, highlights significant going concern issues, with management expressing substantial doubt about the company's ability to continue operations due to insufficient capital and ongoing losses.
NASDAQ
RDHL
Redhill Biopharma LTD
20-F: RedHill Biopharma Reports Financial Results for Year Ended December 31, 2024
RedHill Biopharma releases its 20-F filing, highlighting financial results for the year ended December 31, 2024, and discussing strategic business transactions.
NASDAQ
RDHL
Redhill Biopharma LTD
20-F: RedHill Biopharma Faces Going Concern Uncertainty Despite Net Income in 2023
RedHill Biopharma reports net income for 2023 but acknowledges substantial doubt about its ability to continue as a going concern due to insufficient working capital.